Cerebral Aneurysm Management Market
Market Insights on Cerebral Aneurysm Management covering sales outlook, demand forecast & up-to-date key trends
Cerebral Aneurysm Management Market by Drug Class, Route of Administration, Distribution Channel & Region | Forecast 2023 to 2033
Cerebral Aneurysm Management Market Snapshot
The global cerebral aneurysm management market is expected to garner a market value of US$ 1.56 Billion in 2023 and is expected to accumulate a market value of US$ 2.98 Billion by registering a CAGR of 6.7% in the forecast period 2023-2033. Growth of the cerebral aneurysm management market can be attributed to rise in geriatric population and availability of different medications to treat the ailment. The market for cerebral aneurysm management registered a CAGR of 4% in the historical period 2018-2022
Cerebral aneurysm management refers to the diagnosis and treatment of cerebral aneurysms, which are weak spots in the blood vessels of the brain that can bulge or burst, leading to bleeding in the brain (also known as a subarachnoid hemorrhage). Cerebral aneurysm management typically involves a combination of medical and surgical techniques to diagnose, treat, and prevent the occurrence of aneurysms. The goals of management include reducing the risk of aneurysm rupture, preventing further bleeding if an aneurysm has ruptured, and minimizing any resulting neurological damage.
|
Report Attribute |
Details |
|
Expected Market Value (2023) |
US$ 1.56 Billion |
|
Anticipated Forecast Value (2033) |
US$ 2.98 Billion |
|
Projected Growth Rate (2023-2033) |
6.7% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
2018 to 2022 Cerebral Aneurysm Management Market Demand Analysis vs. Forecast 2023 to 2033
According to market research and competitive intelligence provider Future Market Insights- the market for cerebral aneurysm management reflected a value of 4% during the historical period, 2018 to 2022.
Diagnostic techniques for cerebral aneurysms include imaging tests such as computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, and angiograms. Treatment options may include minimally invasive procedures such as endovascular coiling or stenting, or open surgical procedures such as clipping.
Cerebral aneurysm management is a rapidly evolving field, with new diagnostic and therapeutic techniques being developed and refined to improve patient outcomes. Effective management of cerebral aneurysms requires close collaboration between specialists in neurosurgery, neurology, and interventional radiology.
Thus, the market for cerebral aneurysm management is expected to register a CAGR of 6.7% in the forecast period 2023 to 2033.
Which are Some Prominent Drivers of Cerebral Aneurysm Management Market?
Availability of various treatments driving the growth of cerebral aneurysm management market
The incidence of cerebral aneurysms is increasing worldwide, which is driving demand for effective management and treatment options. The development of minimally invasive techniques and new devices for the treatment of cerebral aneurysms is driving growth in the market.
Surgical Clipping: Involves the placement of a small metal clip at the base of the aneurysm to block blood flow and prevent rupture.
Endovascular Coiling: A minimally invasive procedure where a coil is inserted into the aneurysm through a catheter to fill the sac and prevent blood flow.
Flow Diverter Stenting: A newer endovascular technique where a stent is placed across the neck of the aneurysm to redirect blood flow and shrink the aneurysm.
Observation: For smaller or stable aneurysms that do not show symptoms, regular imaging and monitoring may be recommended to track any changes.
Aging population and government initiatives increasing demand for treatment of cerebral aneurysm
The aging population is more susceptible to cerebral aneurysms, which is leading to increased demand for management and treatment options. Increased public awareness about the symptoms and consequences of cerebral aneurysms is driving demand for early diagnosis and treatment.
Governments around the world are investing in healthcare infrastructure and encouraging innovation in medical technologies, which is driving growth in the market.
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystWhat are the Challenges Faced by the Cerebral Aneurysm Management Market
High cost along with restricted reimbursement creating obstacles for market growth
The cost of treatment for cerebral aneurysms can be high, which can be a barrier for some patients and healthcare systems. There is a shortage of skilled healthcare professionals trained in the diagnosis and treatment of cerebral aneurysms, which can limit access to care.
Reimbursement for cerebral aneurysm treatments can be limited in some countries, which can impact market growth. Strict regulatory requirements for the approval of new devices and treatments can slow market growth and limit access to innovative solutions. The cerebral aneurysm management market faces competition from alternative treatments, such as surgical clipping and endovascular coiling, which can limit market growth.
Region Wise Insights
Prevalence of Cerebral Aneurysm in North America Creating Lucrative Opportunities for Treatment?
Advanced healthcare infrastructure increasing treatment options for cerebral aneurysm
North America has a high incidence of cerebral aneurysms, which is driving demand for effective management and treatment options. Moreover, it has a technologically advanced healthcare infrastructure, with access to cutting-edge treatments and technologies for the management of cerebral aneurysms.
North America is home to some of the leading companies in the cerebral aneurysm management market, which is driving innovation and growth in the market. Reimbursement policies for cerebral aneurysm treatments are favorable in North America, which is driving demand for treatments and contributing to market growth. In addition, the region has high levels of healthcare spending, which is supporting the growth of the cerebral aneurysm management market. Thus, North America is expected to possess 45% market share for cerebral aneurysm management market in 2023.
Increase in Healthcare Spending Driving Growth of Cerebral Aneurysm Management Market in Europe?
Key market players innovating treatment methods for cerebral aneurysm in Europe
The Europe cerebral aneurysm management market refers to the market for medical devices, procedures, and treatments for the diagnosis and treatment of cerebral aneurysms in the European region. This market is expected to grow due to increasing incidence of cerebral aneurysms and advancements in technology. Major players in the market include Johnson & Johnson, Stryker, Medtronic, Terumo, and others. The market growth may be hindered by factors such as high costs of treatments and a lack of awareness about the condition.
The market for cerebral aneurysm management in Europe is growing due to a combination of factors such as increasing incidence, advancements in technology, growing geriatric population, increasing healthcare spending, and increased awareness about the condition. Thus, Europe is expected to possess 37% market share for cerebral aneurysm management market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Category-Wise Insights
Availability of Medication Making Hospital Pharmacies a Favorbale Option for Treating Cerebral Aneurysm?
Favorable reimbursement policies are making hospital pharmacies a viable option for treatment
On the basis of distribution channel, cerebral aneurysm management market is categorized into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
The hospital pharmacy segment is expected to dominate the market, driven by the availability of various treatments and diagnostic options for cerebral aneurysm. The presence of healthcare professionals as well as favorable reimbursement policies, further solidify hospital pharmacies as a preferred choice for treatment.
The growth is also encouraged by government initiatives that support the treatment of cerebral aneurysm in hospital pharmacies. The market share of hospitals for cerebral aneurysm is expected to reach 40% in 2023.
Market Competition
Key players in the cerebral aneurysm management market are Biogen, Pfizer Inc, Hoffmann-La Roche Ltd, Merck Sharp & Dohme Corp, Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Orion Corporation, UCB S.A., Acadia Pharmaceuticals Inc, Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation
- Novartis AG, a key player in the cerebral aneurysm management market is emphasizing on investing in extensive research to develop medications that can alleviate the symptoms associated with cerebral aneurysm.
- Acadia Pharmaceuticals Inc, another key player in the cerebral aneurysm management market is working with healthcare professionals to develop medications to treat immediate after effects of cerebral aneurysm.
Report Scope
|
Report Attribute |
Details |
|
Market Value in 2023 |
US$ 1.56 Billion |
|
Market Value in 2033 |
US$ 2.98 Billion |
|
Growth Rate |
CAGR of 6.7% from 2023 to 2033 |
|
Base Year for Estimation |
2022 |
|
Historical Data |
2018 to 2022 |
|
Forecast Period |
2023 to 2033 |
|
Quantitative Units |
Revenue in USD Billion and CAGR from 2023 to 2033 |
|
Report Coverage |
Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
|
Segments Covered |
|
|
Regions Covered |
|
|
Key Countries Profiled |
|
|
Key Companies Profiled |
|
|
Customization |
Available Upon Request |
Key Segments Profiled in the Cerebral Aneurysm Management Market Survey
Drug Class:
- Antihypertensives
- Antiepileptics
- Analgesics
- Antiemetics
- Antacids
Route of Administration:
- Oral
- Injectable
- Transdermal
Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
Frequently Asked Questions
At what rate did the Cerebral aneurysm management market flourish from 2018-2022?
From 2018-2022, the Cerebral aneurysm management market grew at a CAGR of 4%
What will be the growth rate of the global Cerebral aneurysm management market during the forecast period?
The global Cerebral aneurysm management market is expected to grow with a 6.7% CAGR during 2023 to 2033.
What will be the projected market size of the Cerebral aneurysm management market by 2033?
As of 2033, the Cerebral aneurysm management market is expected to reach US$ 2.98 Billion
Which end user segment is expected to dominate the global Cerebral aneurysm management market during 2033?
Hospital pharmacies are expected to hold 40% of the market share in 2023 for Cerebral aneurysm management market.
How is the North America Cerebral aneurysm management market projected to grow in 2033?
North America is expected to possess 45% market share for Cerebral aneurysm management market in 2023.
How is the Europe Cerebral aneurysm management market projected to grow in 2033?
Europe Cerebral aneurysm management market size is expected to possess 37% market share in 2023.
Table of Content
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 5.3.1. Antihypertensives 5.3.2. Antiepileptics 5.3.3. Analgesics 5.3.4. Antiemetics 5.3.5. Antacids 5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Route of Administration, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 6.3.1. Oral 6.3.2. Injectable 6.3.3. Transdermal 6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 7.1. Introduction / Key Findings 7.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel , 2018 to 2022 7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel , 2023 to 2033 7.3.1. Hospital Pharmacy 7.3.2. Retail Pharmacy 7.3.3. Online Pharmacy 7.4. Y-o-Y Growth Trend Analysis By Distribution Channel , 2018 to 2022 7.5. Absolute $ Opportunity Analysis By Distribution Channel , 2023 to 2033 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. Introduction 8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 8.3.1. North America 8.3.2. Latin America 8.3.3. Europe 8.3.4. South Asia 8.3.5. East Asia 8.3.6. Oceania 8.3.7. MEA 8.4. Market Attractiveness Analysis By Region 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. USA 9.2.1.2. Canada 9.2.2. By Drug Class 9.2.3. By Route of Administration 9.2.4. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Drug Class 9.3.3. By Route of Administration 9.3.4. By Distribution Channel 9.4. Key Takeaways 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Brazil 10.2.1.2. Mexico 10.2.1.3. Rest of Latin America 10.2.2. By Drug Class 10.2.3. By Route of Administration 10.2.4. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Drug Class 10.3.3. By Route of Administration 10.3.4. By Distribution Channel 10.4. Key Takeaways 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. Germany 11.2.1.2. United Kingdom 11.2.1.3. France 11.2.1.4. Spain 11.2.1.5. Italy 11.2.1.6. Rest of Europe 11.2.2. By Drug Class 11.2.3. By Route of Administration 11.2.4. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Drug Class 11.3.3. By Route of Administration 11.3.4. By Distribution Channel 11.4. Key Takeaways 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. India 12.2.1.2. Malaysia 12.2.1.3. Singapore 12.2.1.4. Thailand 12.2.1.5. Rest of South Asia 12.2.2. By Drug Class 12.2.3. By Route of Administration 12.2.4. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Drug Class 12.3.3. By Route of Administration 12.3.4. By Distribution Channel 12.4. Key Takeaways 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. China 13.2.1.2. Japan 13.2.1.3. South Korea 13.2.2. By Drug Class 13.2.3. By Route of Administration 13.2.4. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Drug Class 13.3.3. By Route of Administration 13.3.4. By Distribution Channel 13.4. Key Takeaways 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. Australia 14.2.1.2. New Zealand 14.2.2. By Drug Class 14.2.3. By Route of Administration 14.2.4. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Drug Class 14.3.3. By Route of Administration 14.3.4. By Distribution Channel 14.4. Key Takeaways 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 15.2.1. By Country 15.2.1.1. GCC Countries 15.2.1.2. South Africa 15.2.1.3. Israel 15.2.1.4. Rest of MEA 15.2.2. By Drug Class 15.2.3. By Route of Administration 15.2.4. By Distribution Channel 15.3. Market Attractiveness Analysis 15.3.1. By Country 15.3.2. By Drug Class 15.3.3. By Route of Administration 15.3.4. By Distribution Channel 15.4. Key Takeaways 16. Key Countries Market Analysis 16.1. USA 16.1.1. Pricing Analysis 16.1.2. Market Share Analysis, 2022 16.1.2.1. By Drug Class 16.1.2.2. By Route of Administration 16.1.2.3. By Distribution Channel 16.2. Canada 16.2.1. Pricing Analysis 16.2.2. Market Share Analysis, 2022 16.2.2.1. By Drug Class 16.2.2.2. By Route of Administration 16.2.2.3. By Distribution Channel 16.3. Brazil 16.3.1. Pricing Analysis 16.3.2. Market Share Analysis, 2022 16.3.2.1. By Drug Class 16.3.2.2. By Route of Administration 16.3.2.3. By Distribution Channel 16.4. Mexico 16.4.1. Pricing Analysis 16.4.2. Market Share Analysis, 2022 16.4.2.1. By Drug Class 16.4.2.2. By Route of Administration 16.4.2.3. By Distribution Channel 16.5. Germany 16.5.1. Pricing Analysis 16.5.2. Market Share Analysis, 2022 16.5.2.1. By Drug Class 16.5.2.2. By Route of Administration 16.5.2.3. By Distribution Channel 16.6. United Kingdom 16.6.1. Pricing Analysis 16.6.2. Market Share Analysis, 2022 16.6.2.1. By Drug Class 16.6.2.2. By Route of Administration 16.6.2.3. By Distribution Channel 16.7. France 16.7.1. Pricing Analysis 16.7.2. Market Share Analysis, 2022 16.7.2.1. By Drug Class 16.7.2.2. By Route of Administration 16.7.2.3. By Distribution Channel 16.8. Spain 16.8.1. Pricing Analysis 16.8.2. Market Share Analysis, 2022 16.8.2.1. By Drug Class 16.8.2.2. By Route of Administration 16.8.2.3. By Distribution Channel 16.9. Italy 16.9.1. Pricing Analysis 16.9.2. Market Share Analysis, 2022 16.9.2.1. By Drug Class 16.9.2.2. By Route of Administration 16.9.2.3. By Distribution Channel 16.10. India 16.10.1. Pricing Analysis 16.10.2. Market Share Analysis, 2022 16.10.2.1. By Drug Class 16.10.2.2. By Route of Administration 16.10.2.3. By Distribution Channel 16.11. Malaysia 16.11.1. Pricing Analysis 16.11.2. Market Share Analysis, 2022 16.11.2.1. By Drug Class 16.11.2.2. By Route of Administration 16.11.2.3. By Distribution Channel 16.12. Singapore 16.12.1. Pricing Analysis 16.12.2. Market Share Analysis, 2022 16.12.2.1. By Drug Class 16.12.2.2. By Route of Administration 16.12.2.3. By Distribution Channel 16.13. Thailand 16.13.1. Pricing Analysis 16.13.2. Market Share Analysis, 2022 16.13.2.1. By Drug Class 16.13.2.2. By Route of Administration 16.13.2.3. By Distribution Channel 16.14. China 16.14.1. Pricing Analysis 16.14.2. Market Share Analysis, 2022 16.14.2.1. By Drug Class 16.14.2.2. By Route of Administration 16.14.2.3. By Distribution Channel 16.15. Japan 16.15.1. Pricing Analysis 16.15.2. Market Share Analysis, 2022 16.15.2.1. By Drug Class 16.15.2.2. By Route of Administration 16.15.2.3. By Distribution Channel 16.16. South Korea 16.16.1. Pricing Analysis 16.16.2. Market Share Analysis, 2022 16.16.2.1. By Drug Class 16.16.2.2. By Route of Administration 16.16.2.3. By Distribution Channel 16.17. Australia 16.17.1. Pricing Analysis 16.17.2. Market Share Analysis, 2022 16.17.2.1. By Drug Class 16.17.2.2. By Route of Administration 16.17.2.3. By Distribution Channel 16.18. New Zealand 16.18.1. Pricing Analysis 16.18.2. Market Share Analysis, 2022 16.18.2.1. By Drug Class 16.18.2.2. By Route of Administration 16.18.2.3. By Distribution Channel 16.19. GCC Countries 16.19.1. Pricing Analysis 16.19.2. Market Share Analysis, 2022 16.19.2.1. By Drug Class 16.19.2.2. By Route of Administration 16.19.2.3. By Distribution Channel 16.20. South Africa 16.20.1. Pricing Analysis 16.20.2. Market Share Analysis, 2022 16.20.2.1. By Drug Class 16.20.2.2. By Route of Administration 16.20.2.3. By Distribution Channel 16.21. Israel 16.21.1. Pricing Analysis 16.21.2. Market Share Analysis, 2022 16.21.2.1. By Drug Class 16.21.2.2. By Route of Administration 16.21.2.3. By Distribution Channel 17. Market Structure Analysis 17.1. Competition Dashboard 17.2. Competition Benchmarking 17.3. Market Share Analysis of Top Players 17.3.1. By Regional 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.3.4. By Distribution Channel 18. Competition Analysis 18.1. Competition Deep Dive 18.1.1. Biogen 18.1.1.1. Overview 18.1.1.2. Product Portfolio 18.1.1.3. Profitability by Market Segments 18.1.1.4. Sales Footprint 18.1.1.5. Strategy Overview 18.1.1.5.1. Marketing Strategy 18.1.2. Pfizer Inc. 18.1.2.1. Overview 18.1.2.2. Product Portfolio 18.1.2.3. Profitability by Market Segments 18.1.2.4. Sales Footprint 18.1.2.5. Strategy Overview 18.1.2.5.1. Marketing Strategy 18.1.3. F. Hoffmann-La Roche Ltd 18.1.3.1. Overview 18.1.3.2. Product Portfolio 18.1.3.3. Profitability by Market Segments 18.1.3.4. Sales Footprint 18.1.3.5. Strategy Overview 18.1.3.5.1. Marketing Strategy 18.1.4. Merck Sharp & Dohme Corp. 18.1.4.1. Overview 18.1.4.2. Product Portfolio 18.1.4.3. Profitability by Market Segments 18.1.4.4. Sales Footprint 18.1.4.5. Strategy Overview 18.1.4.5.1. Marketing Strategy 18.1.5. Novartis AG 18.1.5.1. Overview 18.1.5.2. Product Portfolio 18.1.5.3. Profitability by Market Segments 18.1.5.4. Sales Footprint 18.1.5.5. Strategy Overview 18.1.5.5.1. Marketing Strategy 18.1.6. Sanofi 18.1.6.1. Overview 18.1.6.2. Product Portfolio 18.1.6.3. Profitability by Market Segments 18.1.6.4. Sales Footprint 18.1.6.5. Strategy Overview 18.1.6.5.1. Marketing Strategy 18.1.7. Teva Pharmaceutical Industries Ltd. 18.1.7.1. Overview 18.1.7.2. Product Portfolio 18.1.7.3. Profitability by Market Segments 18.1.7.4. Sales Footprint 18.1.7.5. Strategy Overview 18.1.7.5.1. Marketing Strategy 18.1.8. Orion Corporation. 18.1.8.1. Overview 18.1.8.2. Product Portfolio 18.1.8.3. Profitability by Market Segments 18.1.8.4. Sales Footprint 18.1.8.5. Strategy Overview 18.1.8.5.1. Marketing Strategy 18.1.9. UCB S.A. 18.1.9.1. Overview 18.1.9.2. Product Portfolio 18.1.9.3. Profitability by Market Segments 18.1.9.4. Sales Footprint 18.1.9.5. Strategy Overview 18.1.9.5.1. Marketing Strategy 18.1.10. Acadia Pharmaceuticals Inc. 18.1.10.1. Overview 18.1.10.2. Product Portfolio 18.1.10.3. Profitability by Market Segments 18.1.10.4. Sales Footprint 18.1.10.5. Strategy Overview 18.1.10.5.1. Marketing Strategy 18.1.11. H. Lundbeck A/S 18.1.11.1. Overview 18.1.11.2. Product Portfolio 18.1.11.3. Profitability by Market Segments 18.1.11.4. Sales Footprint 18.1.11.5. Strategy Overview 18.1.11.5.1. Marketing Strategy 18.1.12. Mitsubishi Tanabe Pharma Corporation 18.1.12.1. Overview 18.1.12.2. Product Portfolio 18.1.12.3. Profitability by Market Segments 18.1.12.4. Sales Footprint 18.1.12.5. Strategy Overview 18.1.12.5.1. Marketing Strategy 19. Assumptions & Acronyms Used 20. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033 Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 3: Global Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 4: Global Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 5: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 6: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 7: North America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 8: North America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 9: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 10: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 11: Latin America Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 12: Latin America Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 13: Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 14: Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 15: Europe Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 16: Europe Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 17: South Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 18: South Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 19: South Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 20: South Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 21: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 22: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 23: East Asia Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 24: East Asia Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 25: Oceania Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 26: Oceania Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 27: Oceania Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 28: Oceania Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033 Table 29: MEA Market Value (US$ Million) Forecast by Country, 2018 to 2033 Table 30: MEA Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033 Table 31: MEA Market Value (US$ Million) Forecast by Route of Administration, 2018 to 2033 Table 32: MEA Market Value (US$ Million) Forecast by Distribution Channel , 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
Talk to AnalystList of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 2: Global Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 3: Global Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 4: Global Market Value (US$ Million) by Region, 2023 to 2033 Figure 5: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033 Figure 6: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033 Figure 7: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033 Figure 8: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 9: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 10: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 11: Global Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 12: Global Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 13: Global Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 14: Global Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 15: Global Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 16: Global Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 17: Global Market Attractiveness by Drug Class, 2023 to 2033 Figure 18: Global Market Attractiveness by Route of Administration, 2023 to 2033 Figure 19: Global Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 20: Global Market Attractiveness by Region, 2023 to 2033 Figure 21: North America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 22: North America Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 23: North America Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 24: North America Market Value (US$ Million) by Country, 2023 to 2033 Figure 25: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 26: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 27: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 28: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 29: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 30: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 31: North America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 32: North America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 33: North America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 34: North America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 35: North America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 36: North America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 37: North America Market Attractiveness by Drug Class, 2023 to 2033 Figure 38: North America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 39: North America Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 40: North America Market Attractiveness by Country, 2023 to 2033 Figure 41: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 42: Latin America Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 43: Latin America Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 44: Latin America Market Value (US$ Million) by Country, 2023 to 2033 Figure 45: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 46: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 47: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 48: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 49: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 50: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 51: Latin America Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 52: Latin America Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 53: Latin America Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 54: Latin America Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 55: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 56: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 57: Latin America Market Attractiveness by Drug Class, 2023 to 2033 Figure 58: Latin America Market Attractiveness by Route of Administration, 2023 to 2033 Figure 59: Latin America Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 60: Latin America Market Attractiveness by Country, 2023 to 2033 Figure 61: Europe Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 62: Europe Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 63: Europe Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 64: Europe Market Value (US$ Million) by Country, 2023 to 2033 Figure 65: Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 66: Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 67: Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 68: Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 69: Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 70: Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 71: Europe Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 72: Europe Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 73: Europe Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 74: Europe Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 75: Europe Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 76: Europe Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 77: Europe Market Attractiveness by Drug Class, 2023 to 2033 Figure 78: Europe Market Attractiveness by Route of Administration, 2023 to 2033 Figure 79: Europe Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 80: Europe Market Attractiveness by Country, 2023 to 2033 Figure 81: South Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 82: South Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 83: South Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 84: South Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 85: South Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 86: South Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 87: South Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 88: South Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 89: South Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 90: South Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 91: South Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 92: South Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 93: South Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 94: South Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 95: South Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 96: South Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 97: South Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 98: South Asia Market Attractiveness by Route of Administration, 2023 to 2033 Figure 99: South Asia Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 100: South Asia Market Attractiveness by Country, 2023 to 2033 Figure 101: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 102: East Asia Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 103: East Asia Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 104: East Asia Market Value (US$ Million) by Country, 2023 to 2033 Figure 105: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 106: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 107: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 108: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 109: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 110: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 111: East Asia Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 112: East Asia Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 113: East Asia Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 114: East Asia Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 115: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 116: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 117: East Asia Market Attractiveness by Drug Class, 2023 to 2033 Figure 118: East Asia Market Attractiveness by Route of Administration, 2023 to 2033 Figure 119: East Asia Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 120: East Asia Market Attractiveness by Country, 2023 to 2033 Figure 121: Oceania Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 122: Oceania Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 123: Oceania Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 124: Oceania Market Value (US$ Million) by Country, 2023 to 2033 Figure 125: Oceania Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 126: Oceania Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 127: Oceania Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 128: Oceania Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 129: Oceania Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 130: Oceania Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 131: Oceania Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 132: Oceania Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 133: Oceania Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 134: Oceania Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 135: Oceania Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 136: Oceania Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 137: Oceania Market Attractiveness by Drug Class, 2023 to 2033 Figure 138: Oceania Market Attractiveness by Route of Administration, 2023 to 2033 Figure 139: Oceania Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 140: Oceania Market Attractiveness by Country, 2023 to 2033 Figure 141: MEA Market Value (US$ Million) by Drug Class, 2023 to 2033 Figure 142: MEA Market Value (US$ Million) by Route of Administration, 2023 to 2033 Figure 143: MEA Market Value (US$ Million) by Distribution Channel , 2023 to 2033 Figure 144: MEA Market Value (US$ Million) by Country, 2023 to 2033 Figure 145: MEA Market Value (US$ Million) Analysis by Country, 2018 to 2033 Figure 146: MEA Market Value Share (%) and BPS Analysis by Country, 2023 to 2033 Figure 147: MEA Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033 Figure 148: MEA Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033 Figure 149: MEA Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033 Figure 150: MEA Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033 Figure 151: MEA Market Value (US$ Million) Analysis by Route of Administration, 2018 to 2033 Figure 152: MEA Market Value Share (%) and BPS Analysis by Route of Administration, 2023 to 2033 Figure 153: MEA Market Y-o-Y Growth (%) Projections by Route of Administration, 2023 to 2033 Figure 154: MEA Market Value (US$ Million) Analysis by Distribution Channel , 2018 to 2033 Figure 155: MEA Market Value Share (%) and BPS Analysis by Distribution Channel , 2023 to 2033 Figure 156: MEA Market Y-o-Y Growth (%) Projections by Distribution Channel , 2023 to 2033 Figure 157: MEA Market Attractiveness by Drug Class, 2023 to 2033 Figure 158: MEA Market Attractiveness by Route of Administration, 2023 to 2033 Figure 159: MEA Market Attractiveness by Distribution Channel , 2023 to 2033 Figure 160: MEA Market Attractiveness by Country, 2023 to 2033
Recommendations
Explore Healthcare Insights
View Reports
